- Home
- ACRS vs RXST Comparison
ACRS vs RXST Comparison
Compare ACRS & RXST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACRS | RXST |
|---|---|---|
| Founded | 2012 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 311.0M | 300.5M |
| IPO Year | 2015 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ACRS | RXST |
|---|---|---|
| Price | $4.85 | $5.69 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 10 |
| Target Price | ★ $10.20 | $9.78 |
| AVG Volume (30 Days) | ★ 1.3M | 703.2K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 69.01 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $1,683,000.00 | ★ $134,479,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.24 | $10.06 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.22 | $5.30 |
| 52 Week High | $4.94 | $16.73 |
Technical Indicators
Market Signals| Indicator | ACRS | RXST |
|---|---|---|
| Relative Strength Index (RSI) | 64.65 | 31.44 |
| Support Level | $2.67 | N/A |
| Resistance Level | $4.89 | $7.60 |
| Average True Range (ATR) | 0.27 | 0.38 |
| MACD | 0.03 | -0.17 |
| Stochastic Oscillator | 72.12 | 16.81 |
Price Performance
Historical ComparisonAbout ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
About RXST RxSight Inc.
RxSight Inc is a commercial-stage medical technology company dedicated to improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture, and sale of light adjustable lenses and related capital equipment.